Riboxin, 20 mg/ml 5 ml 10 pcs

Pharmacotherapeutic group: metabolic agent.

CodeATH: [С01ЕВ].

Pharmacological properties:

Riboxin is a derivative (nucleoside) of purine, a precursor of adenosine phosphate ATP. It belongs to the group of drugs that stimulate metabolic processes. It has antihypoxic and antiarrhythmic effects. It increases myocardial energy balance, improves coronary circulation, prevents the consequences of intraoperative renal ischemia. It is directly involved in glucose metabolism and promotes metabolism in hypoxia and in the absence of ATP.

It activates pyruvic acid metabolism for normal tissue respiration and promotes activation of xanthine dehydrogenase. It stimulates the synthesis of nucleotides and enhances the activity of some Krebs cycle enzymes. By penetrating into cells, it has a positive effect on metabolic processes in the myocardium – it increases the force of heart contractions and promotes fuller myocardial relaxation in diastole, resulting in an increase in stroke volume. The mechanism of antiarrhythmic action is still unclear.

Reduces platelet aggregation, activates tissue regeneration (especially of the myocardium and the mucosa of the gastrointestinal tract).

Pharmacokinetics

Metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. A small amount is excreted in the urine.

Indications

Complex treatment of myocardial infarction, ischemic heart disease, heart rhythm disorders caused by the use of cardiac glycosides, against the background of myocardiodystrophy after infectious diseases.

Liver diseases (hepatitis, cirrhosis, fatty dystrophy).

Isolated kidney surgery (as pharmacological protection during circulatory arrest).

Active ingredient

Inosin

Composition

1 ml of the solution contains:

active ingredient:

Inosin (riboxin) 20 mg,

excipients: propylene glycol, sodium hydroxide, sodium sulfite anhydrous, water for injection.

How to take, the dosage

The drug is administered intravenously slowly or by drip (40-60 drops per 1 minute). The drug is firstly administered in the form of 200 mg (10 ml of 2% solution) once a day and then, if tolerated well, the dose is increased up to 400 mg (20 ml of 2% solution) 1-2 times a day.

The course of treatment is 10-15 days.

Jet drug administration is possible in acute cardiac arrhythmia in a single dose of 200-400 mg.

For pharmacological protection of renal artery after ischemia the drug is injected intravenously by dosing 1.2 g (60 ml of 2% solution) in 5-15 minutes before renal artery clamping and then another 0.8 g (40 ml of 2% solution) immediately after blood circulation recovery.

When administered by drip injection into a vein 2% solution of the drug is diluted in 5% dextrose (glucose) solution or isotonic sodium chloride solution (up to 250 ml).

Special Instructions

Inosin is prescribed with caution in patients with impaired renal function. If skin itching and hyperemia occur, inosin should be discontinued.

Contraindications

Hypersensitivity to the drug, gout, hyperuricemia, pregnancy, lactation, age under 18 years (effectiveness and safety has not been established). Use with caution in case of renal failure.

Side effects

Allergic reactions: skin itching, skin hyperemia (the drug should be discontinued). Rare: increase of uric acid concentration in blood, exacerbation of gout (with long-term use).

Similarities

Riboxin Bufus, Riboxin-Solofarm